Skip to Content

User Reviews for Fungizone

The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.

Learn more about Fungizone.

Condition	Reviews	Compare	Avg. Ratings

Reviews for Fungizone

No reviews have yet been submitted. Be the first to review this drug.

Learn more about

Micromedex® Care Notes:

Sporotrichosis

More about Fungizone (amphotericin b)

Consumer resources

Other brands: Amphocin

Professional resources

Related treatment guides

Drug Status

Availability Rx Prescription only

Pregnancy Category B No proven risk in humans

CSA Schedule N Not a controlled drug

Approval History Calendar Drug history at FDA

Meningitis

FDA Consumer Updates

More FDA updates

Drug Class

Recently Approved

Amjevita Amjevita (adalimumab-atto) is an anti-TNF-α monoclonal antibody biosimilar to Humira, approved for ...
Exondys 51 Exondys 51 (eteplirsen) is an antisense oligonucleotide indicated for the treatment of Duchenne...
Kyleena Kyleena (levonorgestrel-releasing intrauterine system) is a low-dose progestin-containing...
Yosprala Yosprala (aspirin and omeprazole) is a platelet aggregation inhibitor and proton pump inhibitor...

Related News and Articles

Health Tip: Why Floss? September 9, 2016
Too Few Female Urologists to Meet Aging Patients' Demand August 22, 2016
Health Tip: Hormones Can Affect Women's Dental Health July 26, 2016

Related Questions & Answers

Amphotericin B - What is the stability duration of IV fungizone if it reconstituted and diluted?

Read more questions...

Drugs.com Discount Card

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated Sep 2nd, 2016), Cerner Multum™ (updated Sep 5th, 2016), Wolters Kluwer™ (updated Aug 8th, 2016) and others. To view content sources and attributions, please refer to our editorial policy.